Navigation Links
Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 - ESMO 34 Congress
Date:9/16/2009

THOUSAND OAKS, Calif., Sept. 16 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced it will present detailed data from four Phase 3 studies as well as other data at the ECCO 15 - ESMO 34 European Multidisciplinary Congress, September 20 - 24, 2009 in Berlin, Germany.

Researchers will present data from two Phase 3 head-to-head studies evaluating denosumab versus Zometa(R) (zoledronic acid) for the treatment of bone metastases in patients with advanced breast cancer (the '136' study) and the treatment of bone metastases in advanced cancer patients with solid tumors (not including breast and prostate cancer) or multiple myeloma (the '244' study).

Detailed data will also be presented from two Phase 3 studies evaluating Vectibix(R) (panitumumab) in combination with chemotherapy for the first-line and second-line treatment of metastatic colorectal cancer (the '203' and '181' trials, respectively).

"Amgen is very pleased to be presenting these important data from the denosumab and Vectibix development programs," said Roger M. Perlmutter, M.D., Ph.D., executive vice president of Research and Development at Amgen. "The data from these trials demonstrate that both denosumab and Vectibix have the potential to improve outcomes in patients suffering from cancer."

SELECTED ABSTRACTS OF INTEREST

Identified below are selected abstracts of interest on Amgen research. Updated data will be presented at the meeting.

    Denosumab
    --  A double-blind, randomized study of denosumab versus zoledronic acid
    for the treatment of bone metastases in patients with advanced cancer
    (excluding breast and prostate cancer) or multiple myeloma
        Lead Author: Henry, D.
        Abstract No. 20L
'/>"/>
SOURCE Amgen
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
3. OmniPod(R) Insulin Management System Lets Team Type 1 Members Focus on Competing at Amgen Tour of California
4. Amgen to Present at the Barclays Capital Global Healthcare Conference
5. Amgen Announces Webcast of 2009 First Quarter Financial Results
6. Amgens First Quarter 2009 Adjusted Earnings Per Share Decreased 4 Percent to $1.08
7. Amgen and ONSEdge Partner With Cancer Survivor Jan Ping for New Campaign
8. Amgen to Present at the Deutsche Bank 34th Annual Healthcare Conference
9. Amgen Highlights Data to Be Presented at ASCO
10. Amgens Denosumab and Eli Lillys Forteo/Forsteo Will Drive Robust Annual Growth in the Osteoporosis Drug Market From 2013 to 2018
11. Loyola fellow receives Amgen grant to study treatments for older leukemia patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/26/2014)... It is said that nothing makes a lady ... famous wedding dress supplier, shows its new selection of ... promotion. , UWDress.com’s navy cocktail gowns are the cornerstones ... high fashion styles. Simple dresses in bright neon colors can ... are specially designed for those who want to shine among ...
(Date:12/26/2014)... (PRWEB) December 26, 2014 “Many people ... with personal injury claim issues and phone calls with ... released an article featuring their free eBook on ... helpful eBook on pedestrian and bicycle auto accident claims ... is fully capable of professionally handling their case while ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... CAGR of 7.2% to reach $5,756.0 million by ... the microscopy market. The electron microscopes product segment ... the forecast period. , Rising focus on nanotechnology, ... growth of the microscopy market. , Get Full ...
(Date:12/25/2014)... York (PRWEB) December 25, 2014 Product ... DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to ... According to an Order issued in the U.S. District ... Court will convene an open conference on January 7, ... United States Courthouse in West Palm Beach, Florida. The ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Recently, ... discounts on all its wedding dresses. BellasDress has chosen ... more for gift choices for the holiday season. ... can pick suitable wedding gowns here at discount prices. ... shopping experience at its website. , “All ...
Breaking Medicine News(10 mins):Health News:UWDress.com Shows Its New Navy Cocktail Dresses For 2015 2Health News:Guide to Handling Pedestrian and Bicycle Accidents Released By The Jones Firm, Featured in Recent Article 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... be further explored, researchers say , TUESDAY, Nov. 17 ... likely to die after admission to the hospital with ... suggests. , "After admission to a hospital, trauma ... the study authors wrote. "This concerning finding warrants more ...
... show need for improvement , TUESDAY, Nov. 17 (HealthDay ... job of reducing preterm births, according to a new ... high numbers of early, life-threatening deliveries. , , Vermont ... preterm birth rate under 10 percent, while in Louisiana, ...
... BEACH, Calif., Nov. 17 With these tough economic times, ... gifting this year. Imagine being able to donate to ... and overworked feet. Yoga Sandals® Footwear by Beech Sandal ... feet flexible with 20% of each purchase donated to a ...
... ... working is emerging as the top business objective for employer-sponsored wellness programs around the ... New ... is emerging as the top business objective for employer-sponsored wellness programs around ...
... XOWii is continuing ... was launched in early October, has met with much success. XOWii Thin is looking to ... healthy weight control. , ... November 16, 2009 --The XOWii company has made it their vision to be at the ...
... ... a total settlement of $3.25 million for two sanitation workers whose garbage truck was hit by ... Barnes lawyer Michael Cooper. , ... (Lexis Nexis) November 17, 2009 -- New York law firm Cellino & Barnes ...
Cached Medicine News:Health News:Uninsured Trauma Patients More Likely to Die: Study 2Health News:U.S. Scores a 'D' on Preterm Birth Report Card 2Health News:U.S. Scores a 'D' on Preterm Birth Report Card 3Health News:U.S. Scores a 'D' on Preterm Birth Report Card 4Health News:Give a Gift that Gives Back With Yoga Sandals(R) Comfys 2Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 2Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 3Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 4Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 5Health News:Wellness Survey: Businesses Look to Wellness Programs to Improve Productivity and Lower Absenteeism Stress Cited as Top Health Risk Driving Wellness Programs Around the World 6Health News:XOWii Launches Second Product in its Line of What are Proving to be Impeccably Designed and Unique Products 2Health News:New York Personal Injury Law Firm Cellino & Barnes Wins $3.25 Million Settlement For Workers Injured in Truck Accident 2
(Date:12/24/2014)...  Actavis plc (NYSE: ACT ) ... complete response letter from the U.S. Food and ... (NDA) for the fixed-dose combination (FDC) of nebivolol ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... of a complete response letter, Actavis remains committed ...
(Date:12/24/2014)... 2014 /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... specializes in the patented biopharmaceutical, modernized traditional Chinese ... (API) released unaudited preliminary financial results for the ... Fiscal Year 2015 Ended September 30, 2014 Financial ... with $14.7 million in 1Q14 with gross margins ...
(Date:12/24/2014)... 24, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today that on December 24, 2014 it closed ... The Company raised approximately $2.3 million in gross ... the net proceeds from the offering to fund ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3
... from a Phase III,clinical trial evaluating the efficacy ... the treatment of postmenopausal osteoporosis were,presented at the ... Annual Meeting. In the non-inferiority study comparing risedronate ... [Actonel(R) (risedronate sodium,tablets)] increases in bone mineral density ...
... Medical,Technologies, Inc. (Nasdaq: RMTI ), a ... specialty pharmaceuticals focused on the end-,stage-renal-disease market ... in its Phase IIb dose-ranging study for ... drug. The Phase IIb dose-ranging study ...
Cached Medicine Technology:New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 2New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 3New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 4New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 5New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 6Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4
... Stand Magnifier offers versatility across a ... lens and the light are adjustable. ... hand held objects can be worked ... parallel to the work surface, lay ...
Contour design eyelid implants....
... is made of a high-quality ... of two plano-convex lenses that ... image. This lens design is ... macular degeneration because of the ...
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
Medicine Products: